RBM15 and metabolic dysfunction-associated steatotic liver disease: Compared to those in the control group, the levels of RBM15, EIF3B, YTHDC1, IGF2BP2 and WTAP proteins were significantly lower in the NAFLD group (Fig 11, full blot shown in S9 Fig).